Terran Biosciences, the NY-based biotech platform that develops transformational therapeutics announced the publication of four international PCT patent applications covering novel compounds and potentially improved versions of the empathogens methylone (also called bk-MDMA or MDMC), ethylone, MDEA (aka MDE), MDAI, and MBDB

The company works towards developing distinct therapeutic options tailored to specific patient needs, so that for instance patients with the most severe forms of PTSD may benefit from the most powerful empathogens such as MDMA and MDEA, while patients with milder forms of PTSD, anxiety or depression may benefit from medicines such as MDAI or MBDB. Empathogens are compounds that increase feelings of empathy.

While MDMA has been the most studied one, related compound methylone invented by renowned chemists Alexander Shulgin and Peyton Jacob III has been described as efficacious in treating PTSD through inducing a milder sensorial experience than the former.

Results on which the patent applications are based:

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.